DK1981889T3 - Cytotoksiske midler, der omfatter nye tomaymycin-derivater, og terapeutisk anvendelse deraf - Google Patents

Cytotoksiske midler, der omfatter nye tomaymycin-derivater, og terapeutisk anvendelse deraf

Info

Publication number
DK1981889T3
DK1981889T3 DK07700505.6T DK07700505T DK1981889T3 DK 1981889 T3 DK1981889 T3 DK 1981889T3 DK 07700505 T DK07700505 T DK 07700505T DK 1981889 T3 DK1981889 T3 DK 1981889T3
Authority
DK
Denmark
Prior art keywords
cytotoxic agents
agents including
therapeutic application
including new
tomaymycin derivatives
Prior art date
Application number
DK07700505.6T
Other languages
English (en)
Inventor
Laurence Gauzy
Hervé Bouchard
Alain Commercon
Robert Zhao
Yonghong Deng
Wei Li
Ravi V J Chari
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35953949&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1981889(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of DK1981889T3 publication Critical patent/DK1981889T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
DK07700505.6T 2006-01-25 2007-01-22 Cytotoksiske midler, der omfatter nye tomaymycin-derivater, og terapeutisk anvendelse deraf DK1981889T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06290154A EP1813614B1 (en) 2006-01-25 2006-01-25 Cytotoxic agents comprising new tomaymycin derivatives
PCT/IB2007/000142 WO2007085930A1 (en) 2006-01-25 2007-01-22 Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use

Publications (1)

Publication Number Publication Date
DK1981889T3 true DK1981889T3 (da) 2014-04-14

Family

ID=35953949

Family Applications (2)

Application Number Title Priority Date Filing Date
DK06290154.1T DK1813614T3 (da) 2006-01-25 2006-01-25 Cytotoksiske midler, der omfatter nye tomaymycinderivater
DK07700505.6T DK1981889T3 (da) 2006-01-25 2007-01-22 Cytotoksiske midler, der omfatter nye tomaymycin-derivater, og terapeutisk anvendelse deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK06290154.1T DK1813614T3 (da) 2006-01-25 2006-01-25 Cytotoksiske midler, der omfatter nye tomaymycinderivater

Country Status (39)

Country Link
US (1) US8163736B2 (da)
EP (4) EP1813614B1 (da)
JP (1) JP5116696B2 (da)
KR (1) KR101428112B1 (da)
CN (1) CN101374846B (da)
AR (1) AR059201A1 (da)
AT (1) ATE527262T1 (da)
AU (1) AU2007209072C1 (da)
BR (1) BRPI0707264A2 (da)
CA (1) CA2635482C (da)
CR (1) CR10149A (da)
CY (2) CY1112495T1 (da)
DK (2) DK1813614T3 (da)
DO (1) DOP2007000016A (da)
EA (1) EA017196B1 (da)
EC (1) ECSP088632A (da)
ES (2) ES2374964T3 (da)
GT (1) GT200800147A (da)
HK (1) HK1129106A1 (da)
HN (1) HN2008001103A (da)
HR (2) HRP20110955T1 (da)
IL (1) IL192472A0 (da)
MA (1) MA30226B1 (da)
ME (1) ME01814B (da)
MX (1) MX2008009582A (da)
MY (1) MY157715A (da)
NI (1) NI200800207A (da)
NO (1) NO341074B1 (da)
NZ (1) NZ569789A (da)
PE (1) PE20071110A1 (da)
PL (2) PL1813614T3 (da)
PT (2) PT1813614E (da)
RS (2) RS52060B (da)
SI (2) SI1813614T1 (da)
TN (1) TNSN08283A1 (da)
TW (1) TWI389909B (da)
UA (1) UA97794C2 (da)
WO (1) WO2007085930A1 (da)
ZA (1) ZA200805649B (da)

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2658276A1 (en) 2006-07-18 2008-01-24 Sanofi-Aventis Antagonist antibody for the treatment of cancer
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
PT2019104E (pt) * 2007-07-19 2013-12-03 Sanofi Sa Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica
GB0819097D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
US8426402B2 (en) 2009-02-05 2013-04-23 Immunogen, Inc. Benzodiazepine derivatives
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
EP2558475A1 (en) 2010-04-15 2013-02-20 Spirogen Sàrl Pyrrolobenzodiazepines used to treat proliferative diseases
WO2011130613A1 (en) * 2010-04-15 2011-10-20 Seattle Genetics, Inc. Targeted pyrrolobenzodiazapine conjugates
MA34277B1 (fr) * 2010-04-15 2013-06-01 Spirogen Developments Sarl Pyrrolobenzodiazépines et conjugués de celles-ci
FR2963007B1 (fr) * 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
MX343337B (es) 2011-02-15 2016-11-01 Immunogen Inc Metodos de preparacion de conjugados.
US9156854B2 (en) 2011-04-18 2015-10-13 Immunogen, Inc. Maytansinoid derivatives with sulfoxide linker
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
EP2751120B1 (en) 2011-09-20 2018-08-22 MedImmune Limited Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates
BR112014008888A2 (pt) 2011-10-14 2017-04-18 Seattle Genetics Inc pirrolobenzodiazepinas
US9388187B2 (en) 2011-10-14 2016-07-12 Medimmune Limited Pyrrolobenzodiazepines
EP2755642B1 (en) 2011-10-14 2018-07-18 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
EP3309162A1 (en) 2011-10-14 2018-04-18 Seattle Genetics, Inc. Targeted conjugates of pyrrolobenzodiazepines
EA026827B1 (ru) * 2011-10-14 2017-05-31 Медимьюн Лимитед Пирролбензодиазепины и их конъюгаты
HUE037021T2 (hu) 2012-02-24 2018-08-28 Abbvie Stemcentrx Llc DLL3- modulátorok és eljárások alkalmazásukra
EP3539985A1 (en) 2012-02-24 2019-09-18 AbbVie Stemcentrx LLC Anti sez6 antibodies and methods of use
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
KR20150006000A (ko) 2012-05-01 2015-01-15 제넨테크, 인크. 항-pmel17 항체 및 면역접합체
KR102557309B1 (ko) 2012-05-15 2023-07-20 씨젠 인크. 자가-안정화 링커 접합체
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
PE20150615A1 (es) 2012-07-09 2015-05-28 Genentech Inc Inmunoconjugados que comprenden un anticuerpo anti-cd22 ligado a una pirrolobenzodiazepina
EP2869850B1 (en) 2012-07-09 2017-08-23 Genentech, Inc. Immunoconjugates comprising anti-cd79b antibodies
CA2879665A1 (en) 2012-08-02 2014-02-06 Genentech, Inc. Anti-etbr antibodies and immunoconjugates
EP2887965A1 (en) 2012-08-22 2015-07-01 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
HUE039329T2 (hu) 2012-10-12 2018-12-28 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
US10751346B2 (en) 2012-10-12 2020-08-25 Medimmune Limited Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
CA2885315C (en) 2012-10-12 2020-06-23 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9745303B2 (en) 2012-10-12 2017-08-29 Medimmune Limited Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
SI2766048T1 (sl) 2012-10-12 2015-03-31 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
US10736903B2 (en) 2012-10-12 2020-08-11 Medimmune Limited Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
KR101995621B1 (ko) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항-cd22 항체 컨주게이트
PT2906298T (pt) 2012-10-12 2018-12-28 Medimmune Ltd Conjugados de pirrolobenzodiazepina-anticorpos
ES2701076T3 (es) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
ES2658888T5 (es) 2012-12-21 2021-10-19 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas
EP2745876A1 (en) 2012-12-21 2014-06-25 Prous Institute for Biomedical Research, S.A. Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
AU2014218730B2 (en) 2013-02-22 2018-12-13 Abbvie Stemcentrx Llc Novel antibody conjugates and uses thereof
CA2901941C (en) 2013-03-13 2020-04-07 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
NZ712035A (en) 2013-03-13 2019-06-28 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
BR112015021965B1 (pt) 2013-03-13 2022-05-03 Medimmune Limited Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica, uso dos mesmos para o tratamento de uma doença proliferativa e método de síntese dos ditos compostos
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
CN105189552B (zh) 2013-03-14 2019-08-02 基因泰克公司 抗b7-h4抗体和免疫缀合物
US10442836B2 (en) 2013-08-12 2019-10-15 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
CN105848671B (zh) 2013-08-28 2019-12-13 艾伯维施特姆森特克斯有限责任公司 位点特异性抗体缀合方法和组合物
BR112016004245A2 (pt) 2013-08-28 2017-10-17 Stemcentrx Inc moduladores de sez6 e métodos de uso
CN115124573A (zh) * 2013-09-02 2022-09-30 杭州多禧生物科技有限公司 应用于细胞结合分子-药物共轭体的新型细胞毒性分子
KR20160055252A (ko) 2013-09-17 2016-05-17 제넨테크, 인크. 항-lgr5 항체의 사용 방법
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
AU2014337555C1 (en) 2013-10-15 2021-01-28 Seagen Inc. PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics
CA2928671A1 (en) 2013-11-06 2015-05-14 Stemcentrx, Inc. Novel anti-claudin antibodies and methods of use
JP2017500028A (ja) 2013-12-12 2017-01-05 アッヴィ・ステムセントルクス・エル・エル・シー 新規の抗ｄｐｅｐ３抗体および使用方法
SG11201604784XA (en) 2013-12-13 2016-07-28 Genentech Inc Anti-cd33 antibodies and immunoconjugates
CN105828840B (zh) 2013-12-16 2020-08-04 基因泰克公司 1-(氯甲基)-2,3-二氢-1H-苯并[e]吲哚二聚体抗体-药物缀合物化合物及使用和治疗方法
CA3211226A1 (en) 2014-02-11 2015-08-20 Seagen Inc. Selective reduction of proteins
KR20170008202A (ko) 2014-02-21 2017-01-23 애브비 스템센트알엑스 엘엘씨 흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체
WO2015127685A1 (en) 2014-02-28 2015-09-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
GB201407816D0 (en) 2014-05-02 2014-06-18 King S College London Pyrrolobenzodiazepine Compounds
WO2015179658A2 (en) 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
WO2016008112A1 (en) 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
ES2913865T3 (es) 2014-08-28 2022-06-06 Bioatla Inc Receptores de antígeno quimérico condicionalmente activos para células T modificadas
EP3188761A4 (en) * 2014-09-02 2018-04-18 ImmunoGen, Inc. Methods for formulating antibody drug conjugate compositions
TW201613930A (en) 2014-09-03 2016-04-16 Immunogen Inc Cytotoxic benzodiazepine derivatives
SI3189056T1 (sl) 2014-09-03 2020-10-30 Immunogen, Inc. Citotoksični derivati benzodiazepinov
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
PL3191135T3 (pl) 2014-09-12 2021-01-25 Genentech, Inc. Przeciwciała i immunokoniugaty anty-HER2
WO2016040724A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
AR101846A1 (es) 2014-09-12 2017-01-18 Genentech Inc Anticuerpos anti-cll-1 e inmunoconjugados
KR20170052600A (ko) 2014-09-12 2017-05-12 제넨테크, 인크. 시스테인 가공된 항체 및 콘주게이트
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EA201790359A1 (ru) 2014-09-17 2017-08-31 Дженентек Инк. Пирролобензодиазепины и их конъюгаты, связанные дисульфидной связью с антителами
MX2017003472A (es) 2014-09-17 2017-10-31 Genentech Inc Inmunoconjugados que comprenden anticuerpos anti-her2.
BR112017011111A2 (pt) 2014-11-25 2017-12-26 Adc Therapeutics Sa conjugados de pirrolobenzodiazepina-anticorpo
JP6676058B2 (ja) 2015-01-14 2020-04-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法
US9527871B2 (en) 2015-01-14 2016-12-27 Bristol-Myers Squibb Company Benzodiazepine dimers, conjugates thereof, and methods of making and using
US9504694B2 (en) * 2015-03-19 2016-11-29 Cellerant Therapeutics, Inc. Isoquinolidinobenzodiazepines
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
BR112017027258A2 (pt) 2015-06-23 2018-08-28 Bristol-Myers Squibb Company dímeros de benzodiazepina macrocíclicos, conjugados dos mesmos, preparação e usos
CN113350518A (zh) 2015-07-12 2021-09-07 杭州多禧生物科技有限公司 与细胞结合分子的共轭偶联的桥连接体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CN113004288A (zh) 2015-07-21 2021-06-22 伊缪诺金公司 制备细胞毒性苯并二氮杂䓬衍生物的方法
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP7073266B2 (ja) 2016-03-25 2022-05-23 シージェン インコーポレイテッド Ｐｅｇ化薬物リンカー及びその中間体を調製するためのプロセス
SG11201808994YA (en) 2016-04-15 2018-11-29 Bioatla Llc Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
US10934359B2 (en) 2016-04-21 2021-03-02 Abbvie Stemcentrx Llc Anti-BMPR1B antibodies and methods of use
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
TW201808336A (zh) 2016-05-11 2018-03-16 賽諾菲公司 用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案
SI3455261T1 (sl) 2016-05-13 2023-01-31 Bioatla, Inc. Protitelesa proti ROR2, fragmenti protitelesa, njihovi imunokonjugati in uporabe le-teh
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
CA3031559A1 (en) 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
KR20190038579A (ko) 2016-08-09 2019-04-08 시애틀 지네틱스, 인크. 개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체
CN109689111B (zh) 2016-08-11 2024-04-05 基因泰克公司 吡咯并苯并二氮杂䓬前药及其抗体缀合物
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
CN116143678A (zh) 2016-11-14 2023-05-23 杭州多禧生物科技有限公司 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
EP3468991A1 (en) 2016-11-21 2019-04-17 cureab GmbH Anti-gp73 antibodies and immunoconjugates
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
CA3045902A1 (en) 2016-12-21 2018-06-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for flt3 and uses thereof
BR112019016373B1 (pt) 2017-02-08 2022-01-25 Medimmune Limited Conjugado anticorpo-fármaco que se liga ao axl, composição e composição farmacêutica que compreende o mesmo e uso terapêutico do dito conjugado
PL3579883T3 (pl) 2017-02-08 2022-01-24 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
IL269398B2 (en) 2017-03-24 2024-05-01 Seagen Inc A process for the preparation of glucuronide-drug binders and their intermediates
PT3612537T (pt) 2017-04-18 2022-08-29 Medimmune Ltd Conjugados de pirrolobenzodiazepina
TW201839001A (zh) 2017-04-20 2018-11-01 美商伊繆諾金公司 細胞毒性苯并二氮平衍生物及其綴合物
JP7408396B2 (ja) 2017-04-20 2024-01-05 アーデーセー セラピューティクス ソシエテ アノニム 併用療法
AU2018268970A1 (en) 2017-05-19 2019-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
AU2018285562B2 (en) 2017-06-14 2024-01-18 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
CA3066953A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. Human monoclonal antibodies specific for cd33 and methods of their use
EA039276B1 (ru) 2017-08-18 2021-12-27 Медимьюн Лимитед Пирролобензодиазепиновые конъюгаты
IL302943A (en) 2017-09-20 2023-07-01 Ph Pharma Co Ltd Thylanstatin analogs
IL301638B1 (en) 2017-09-29 2024-05-01 Daiichi Sankyo Co Ltd Conjugation of an antibody with a pyrrolobenzodiazepine derivative
BR112020008676A2 (pt) * 2017-11-02 2020-10-27 Ube Industries, Ltd. composto, e, composição farmacêutica.
EP3710066B1 (en) 2017-11-14 2022-06-08 Medimmune Limited Pyrrolobenzodiazepine conjugates
EP3732178A1 (en) 2017-12-28 2020-11-04 ImmunoGen, Inc. Benzodiazepine derivatives
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN112203696A (zh) 2018-05-25 2021-01-08 免疫医疗有限公司 吡咯并苯并二氮杂*缀合物
US11939377B2 (en) 2018-07-12 2024-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured CD22-specific monoclonal antibody and uses thereof
WO2020025108A1 (en) 2018-07-31 2020-02-06 Astrazeneca Ab Linkers and conjugates
EP3833684A1 (en) 2018-08-08 2021-06-16 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity monoclonal antibodies targeting glypican-2 and uses thereof
CA3112977A1 (en) 2018-10-19 2020-04-23 Medimmune Limited Pyrrolobenzodiazepine conjugates
KR20210081350A (ko) 2018-10-19 2021-07-01 메드임뮨 리미티드 피롤로벤조디아제핀 컨쥬게이트
GB201820725D0 (en) 2018-12-19 2019-01-30 Adc Therapeutics Sarl Pyrrolobenzodiazepine resistance
US20220347309A1 (en) 2018-12-19 2022-11-03 Adc Therapeutics Sa Pyrrolobenzodiazepine resistance
MX2021007368A (es) 2018-12-21 2021-07-15 Avidity Biosciences Inc Anticuerpos anti-receptor de transferrina y usos de los mismos.
US20220096641A1 (en) * 2019-01-03 2022-03-31 Legochem Biosciences, Inc. Pyrrolobenzodiazepine dimer compound with improved safety and use thereof
US20220064324A1 (en) 2019-01-08 2022-03-03 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting mesothelin for treating solid tumors
WO2020154150A1 (en) 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND THEIR USES
CA3130174A1 (en) 2019-03-15 2020-09-24 Medimmune Limited Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
EP3947395A1 (en) 2019-03-29 2022-02-09 ImmunoGen, Inc. Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases
HUE060364T2 (hu) 2019-03-29 2023-02-28 Medimmune Ltd Vegyületek és konjugátumaik
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN110483504B (zh) * 2019-08-02 2022-04-26 桂林理工大学 以DMF为甲酰化试剂构建2-(2-萘基)咪唑[1,2-a]吡啶-3-醛的新方法
WO2021074392A1 (en) * 2019-10-16 2021-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Visual detection of pbd induced dna crosslinks
WO2021081052A1 (en) 2019-10-22 2021-04-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
US20240123081A1 (en) 2019-10-25 2024-04-18 Medimmune, Llc Branched moiety for use in conjugates
CA3161573A1 (en) 2019-12-12 2021-06-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates specific for cd276 and uses thereof
TW202140076A (zh) 2020-01-22 2021-11-01 英商梅迪繆思有限公司 化合物及其軛合物
MX2022009052A (es) 2020-01-22 2022-08-15 Medimmune Ltd Compuestos y conjugados de estos.
IL310900A (en) 2020-03-19 2024-04-01 Avidity Biosciences Inc Preparations and methods for the treatment of facial, back and arm muscle atrophy
CA3177180A1 (en) 2020-03-27 2021-09-30 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy
AU2021251875A1 (en) 2020-04-10 2022-11-03 Seagen Inc. Charge variant linkers
WO2022093745A1 (en) 2020-10-26 2022-05-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
MX2023010902A (es) 2021-03-18 2023-09-27 Seagen Inc Liberacion selectiva de farmacos a partir de conjugados internalizados de compuestos biologicamente activos.
JP2024511360A (ja) 2021-03-18 2024-03-13 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
GB202105187D0 (en) 2021-04-12 2021-05-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB202105186D0 (en) 2021-04-12 2021-05-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
EP4352099A1 (en) 2021-06-09 2024-04-17 The United States of America, as represented by The Secretary, Department of Health and Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
WO2023288252A1 (en) 2021-07-13 2023-01-19 Truebinding, Inc. Methods of preventing protein aggregation
GB202110726D0 (en) 2021-07-26 2021-09-08 Cambridge Entpr Ltd Conjugating reagents and conjugates thereof
AU2022345098A1 (en) 2021-09-16 2024-04-04 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
TW202406934A (zh) 2022-05-03 2024-02-16 美商建南德克公司 抗Ｌｙ６Ｅ抗體、免疫結合物及其用途
GB202207691D0 (en) 2022-05-25 2022-07-06 Cambridge Entpr Ltd Quinone protected forms and conjugates

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1516743A (fr) 1966-04-01 1968-02-05 Rhone Poulenc Sa Nouvel antibiotique et son procédé de préparation par culture de streptomyces croceus
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4764368A (en) 1984-08-29 1988-08-16 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
WO1991013080A1 (en) 1990-02-20 1991-09-05 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
EP1109812B1 (en) 1998-08-27 2005-05-04 Spirogen Limited Pyrrolobenzodiazepines
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
US6472056B1 (en) 1999-07-06 2002-10-29 Northwest Coatings Corp. Radiation-cured laminate label
JP2003514903A (ja) 1999-11-24 2003-04-22 イムノージェン インコーポレーテッド タキサンを含有する細胞傷害薬とその治療への利用
WO2001095857A2 (en) * 2000-06-16 2001-12-20 Mitra Medical Technology Ab Reusable extracorporeal colums loaded with ligand-dibiotin conjugates
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
EP1608663B1 (en) * 2003-03-31 2008-11-05 Council of Scientific and Industrial Research Pyrrolo (2,1-c)(1,4) benzodiazepines dimers as antitumour agents and process thereof
MX370281B (es) 2003-05-20 2019-12-09 Immunogen Inc Agentes citotóxicos mejorados que comprenden nuevos maitansinoides.
EP1675857B1 (en) 2003-10-22 2011-07-13 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
GB0416511D0 (en) * 2003-10-22 2004-08-25 Spirogen Ltd Pyrrolobenzodiazepines
GB0404577D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
GB0404578D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
US7528126B2 (en) 2004-03-09 2009-05-05 Spirogen Limited Pyrrolobenzodiazepines
GB0410725D0 (en) * 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents

Also Published As

Publication number Publication date
HN2008001103A (es) 2011-12-01
EA017196B1 (ru) 2012-10-30
ECSP088632A (es) 2008-08-29
SI1981889T1 (sl) 2014-05-30
NO341074B1 (no) 2017-08-21
UA97794C2 (ru) 2012-03-26
IL192472A0 (en) 2009-02-11
PT1981889E (pt) 2014-04-29
US8163736B2 (en) 2012-04-24
KR20080097435A (ko) 2008-11-05
EP1981889B1 (en) 2014-01-15
SI1813614T1 (sl) 2012-01-31
PT1813614E (pt) 2012-01-09
KR101428112B1 (ko) 2014-08-07
ES2457525T3 (es) 2014-04-28
HRP20110955T1 (hr) 2012-01-31
EP1981889A1 (en) 2008-10-22
EP2386559A1 (en) 2011-11-16
TWI389909B (zh) 2013-03-21
TNSN08283A1 (en) 2009-10-30
DOP2007000016A (es) 2007-09-15
RS53293B (en) 2014-08-29
ES2374964T3 (es) 2012-02-23
JP5116696B2 (ja) 2013-01-09
TW200806668A (en) 2008-02-01
AU2007209072A1 (en) 2007-08-02
MY157715A (en) 2016-07-15
JP2009524636A (ja) 2009-07-02
MA30226B1 (fr) 2009-02-02
ATE527262T1 (de) 2011-10-15
PL1981889T3 (pl) 2014-06-30
RS52060B (en) 2012-04-30
EP1813614B1 (en) 2011-10-05
PL1813614T3 (pl) 2012-03-30
CY1115199T1 (el) 2017-01-04
ZA200805649B (en) 2009-11-25
HRP20140307T1 (hr) 2014-06-20
AR059201A1 (es) 2008-03-19
CR10149A (es) 2008-10-29
MX2008009582A (es) 2008-11-26
EP1813614A1 (en) 2007-08-01
GT200800147A (es) 2012-03-12
NO20083427L (no) 2008-10-14
ME01814B (me) 2014-09-20
NZ569789A (en) 2011-11-25
DK1813614T3 (da) 2012-01-23
EA200870193A1 (ru) 2009-02-27
EP2371827A1 (en) 2011-10-05
PE20071110A1 (es) 2007-12-21
US20090036431A1 (en) 2009-02-05
AU2007209072B2 (en) 2012-09-27
CA2635482C (en) 2012-05-22
BRPI0707264A2 (pt) 2011-04-26
AU2007209072C1 (en) 2013-03-14
NI200800207A (es) 2010-07-15
CN101374846A (zh) 2009-02-25
HK1129106A1 (en) 2009-11-20
CN101374846B (zh) 2013-10-30
WO2007085930A1 (en) 2007-08-02
CA2635482A1 (en) 2007-08-02
CY1112495T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
DK1981889T3 (da) Cytotoksiske midler, der omfatter nye tomaymycin-derivater, og terapeutisk anvendelse deraf
DK2019104T3 (da) Cytotoksiske midler, der omfatter nye tomaymycinderivater, og terapeutisk anvendelse deraf
DK2049525T3 (da) N-laminoheteroaryl)-1H-indol-2-carboxamid-derivater, og fremstilling og terapeutisk anvendelse deraf
IL193467A0 (en) Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
IL204663A0 (en) Nicotinamide derivatives, preparastion thereof and therapeutic use thereof
EP2030974A4 (en) Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents
HK1137027A1 (en) Pyrrolo-nitrogenous heterocyclic derivatives and the pharmaceutical use thereof
DK2207773T3 (da) Heterocyklisk forbindelse og farmaceutisk sammensætning deraf.
IL202034A (en) Heterocyclic derivatives of indazole and drugs and their use
ATE420081T1 (de) Trifluormethylbenzamidderivate und therapeutische verwendungen dafür
DK2059508T3 (da) 5,6-bisaryl-2-pyridin-carboxamidderivater, fremstilling deraf og terapeutisk anvendelse deraf som urotensin II-receptorantagonister
BRPI0816992A2 (pt) Derivado heterocíclico tricícloco, e, composição farmacêutica
DK1773829T3 (da) Aminotropanderivater, fremstilling og terapeutiske anvendelser heraf
DK2188253T3 (da) Indol-2-onderivater, der er disubstitueret i 3-stillingen, fremstilling deraf og terapeutisk anvendelse deraf
DK1912644T3 (da) N-(arylalkyl)-1h-pyrrolopyridin-2-carboxamid-derivater, fremstilling deraf og terapeutisk anvendelse deraf
BRPI0819202A2 (pt) Derivado heterocíclico, e, composição farmacêutica
ATE460415T1 (de) Therapeutische pyrazoloä3,4-büpyridine und - indazole
DK1940840T3 (da) 6-heteroarylpyridoindolon-derivater, fremstilling deraf og terapeutisk anvendelse deraf
EP2145889A4 (en) HETEROCYCLIC FUSED CORE DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE DERIVATIVE, AND USE OF THE COMPOSITION FOR MEDICAL PURPOSES
IL193172A0 (en) Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents
DK2234966T3 (da) Azetidinderivater, fremstilling og terapeutisk anvendelse heraf
DK2118104T3 (da) Azabicycloalkanderivater, fremstilling og terapeutisk anvendelse heraf
DK2106401T3 (da) Derivater af pyrrolopyridin-2-carboxamider, fremstilling deraf og terapeutisk anvendelse deraf
DK1976853T3 (da) Nye forbindelser og anvendelse heraf